Core Viewpoint - The company Shijiazhuang Pharmaceutical Group has received production registration approvals from the National Medical Products Administration of China for several pharmaceutical products, indicating significant progress in its product portfolio and market positioning [1] Group 1: Product Approvals - The company has obtained production registration for Aminophylline Tablets (100mg), classified as a Class 3 chemical drug, making it the third domestic company to receive such approval [1] - Aminophylline Tablets are primarily used for alleviating symptoms of bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema, and can also treat asthma caused by cardiogenic pulmonary edema [1] - The company's raw material for Aminophylline has also been approved for use in marketed formulations by the National Medical Products Administration [1] Group 2: Additional Product Approvals - The company has also secured production registration for Hydrochloride of Picarbital Inhalation Solution (0.5ml: 50μg) and Injection of Dihydrosodium Adenosine Triphosphate (0.5g), classified as Class 3 and Class 4 chemical drugs respectively [1] - Hydrochloride of Picarbital Inhalation Solution is mainly used to relieve symptoms associated with bronchial asthma, chronic bronchitis, and emphysema with airflow limitation [1] - Injection of Dihydrosodium Adenosine Triphosphate is primarily used for treating intrahepatic cholestasis caused by liver cirrhosis and cholestasis during pregnancy [1]

Core Viewpoint - The company has received production registration approvals from the National Medical Products Administration for several pharmaceutical products, indicating a significant advancement in its product portfolio and market position in the pharmaceutical industry [1] Group 1: Product Approvals - The company has obtained the production registration approval for Aminophylline Tablets (100mg), classified as a Class 3 chemical drug, making it the third domestic company to receive such approval [1] - Aminophylline Tablets are primarily used for alleviating symptoms of bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema, and can also be used to treat asthma caused by cardiogenic pulmonary edema [1] - The company’s Aminophylline raw material has also been approved for use in marketed formulations by the National Medical Products Administration [1] Group 2: Additional Product Approvals - The company has secured production registration approvals for Salbutamol Inhalation Solution (0.5ml: 50μg) and Injection Adenosine Methionine (0.5g), classified as Class 3 and Class 4 chemical drugs, respectively [1] - Salbutamol Inhalation Solution is mainly used to relieve symptoms associated with bronchial asthma, chronic bronchitis, and emphysema based on airflow limitation [1] - Injection Adenosine Methionine is primarily used for treating intrahepatic cholestasis caused by liver cirrhosis and cholestasis during pregnancy [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局（「國家藥監局」）有關氨茶鹼片（100mg）的藥品生產 註冊批件，屬於化學藥品第3類，視同通過一致性評價，是國內企業第三家獲批。氨茶鹼片主要 用於支氣管哮喘、喘息型支氣管炎、阻塞性肺氣腫等緩解喘息症狀，也可用於治療心源性肺水 腫引起的哮喘。本集團的氨茶鹼原料藥已獲國家藥監局批准登記成為在上市製劑使用的原料藥。 董事局亦欣然公告，本集團已取得國家藥監局有關鹽酸丙卡特羅吸入溶液(0.5ml：50μg)及注射 用丁二磺酸腺苷蛋氨酸(0.5g)的藥品生產註冊批件，分別屬於化學藥品第3類及第4類，視同通 過一致性評價。鹽酸丙卡特羅吸入溶液主要用於緩解支氣管哮喘、慢性支氣管炎及肺氣腫以氣 流受限為基礎的各種症狀。注射用丁二磺酸腺苷蛋氨酸主要用於治療肝硬化前和肝 ...

Core Viewpoint - Haizheng Pharmaceutical (600267) and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., participated in the 11th batch of national centralized drug procurement organized by the Joint Procurement Office, with three products expected to win bids in this procurement process [1] Group 1 - The company announced its participation in the national centralized drug procurement bidding on October 29 [1] - The Joint Procurement Office published the proposed winning results for the procurement on October 28, 2025 [1] - The three products that are expected to win bids include Pravastatin Sodium Tablets, Injection Adenosine Methionine, and Aicuo Bopamine Ethanolamine Tablets [1]

Group 1 - The core point of the article is that Zhejiang Haizheng Pharmaceutical Co., Ltd. and its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., participated in the 11th national centralized procurement organized by the Joint Procurement Office, with three products expected to win bids [1] - The three products that are likely to be awarded in the centralized procurement include Pravastatin Sodium Tablets, with projected sales revenue of 54.2 million yuan for the first half of 2025, Injection AdoMet, with projected sales revenue of 88.96 million yuan, and Eltrombopag Ethanolamine Tablets, with projected sales revenue of 740,000 yuan [1] - As of the report, Haizheng Pharmaceutical has a market capitalization of 13.2 billion yuan [1] Group 2 - In 2024, the revenue composition of Haizheng Pharmaceutical is expected to be: 58.46% from pharmaceutical manufacturing, 39.29% from drug sales, 1.94% from other industries, 0.23% from other businesses, and 0.08% from CMO/CDMO/CRO services [1]

Core Viewpoint - Pro Pharmaceutical (000739) announced that its subsidiary, Zhejiang Pro Kangyu Pharmaceutical Co., Ltd., has participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with its product, injection adenosine methionine bisulfate, expected to be selected for this procurement [1] Group 1 - The selected product is anticipated to obtain the Drug Registration Certificate in November 2024, which is equivalent to passing the consistency evaluation of generic drug quality and efficacy [1]

Group 1 - Prolo Pharmaceutical's subsidiary, Zhejiang Prolo Kangyu Pharmaceutical Co., Ltd., participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with its product, injection adenosine methionine bisulfate, expected to be selected for this procurement [1] - For the first half of 2025, Prolo Pharmaceutical's revenue composition is projected to be 99.6% from the pharmaceutical industry and 0.4% from other businesses [1] - As of the report date, Prolo Pharmaceutical has a market capitalization of 17.9 billion yuan [1]

Core Viewpoint - Pro Pharmaceutical (000739) announced that its subsidiary Zhejiang Pro Kangyu Pharmaceutical Co., Ltd. participated in the 11th batch of national centralized drug procurement, with its product, injection adenosine methionine bisulfate, expected to be selected [1] Group 1: Product and Market Impact - The selected product is indicated for conditions such as pre-cirrhosis and intrahepatic cholestasis due to cirrhosis, as well as intrahepatic cholestasis during pregnancy [1] - If the company signs the procurement contract and implements it, it will help expand the sales scale of the related product and increase market share [1] - The potential selection of the product is expected to have a positive impact on the company's future operating performance [1] Group 2: Uncertainty and Future Steps - The procurement contract for the selected product has not yet been signed, indicating uncertainty in subsequent matters [1]

Group 1 - Changhua Group received a product purchase contract for carbon-ceramic brake discs, with a total sales amount expected to exceed 100 million yuan over a 5-year lifecycle, starting mass production in Q2 2026 [1] - Zhongke Environmental reported a net profit of 196 million yuan for the first half of 2025, a year-on-year increase of 19.83%, with revenue of 848 million yuan, up 4.48% [1] - WuXi AppTec's net profit for the first half of 2025 grew by 101.92% to 8.561 billion yuan, with revenue of 20.799 billion yuan, a 20.64% increase [1][2] - Sujiao Technology's net profit decreased by 39.54% to 95.39 million yuan, with revenue down 13.75% to 1.776 billion yuan [1] - Jucheng Co. reported a net profit of 205 million yuan, a significant increase of 43.5%, with revenue of 575 million yuan, up 11.69% [1] Group 2 - Sanxiang New Materials plans to invest up to 300 million yuan in a zirconium-hafnium separation project, with a production capacity of 20,000 tons [1] - Koweil received government subsidies totaling 4.9752 million yuan, accounting for 10.14% of its audited net profit [1] - Xinhua Medical obtained two Class II medical device registration certificates for digital X-ray machines [1] - Huanxu Electronics reported a net profit of 638 million yuan, down 18.66%, with total revenue of 27.214 billion yuan, a slight decrease of 0.63% [1] - Zhenhua Co.'s general manager was fined 100,000 yuan for violations related to stock trading by his child [1] Group 3 - Huafeng Aluminum signed a raw material purchase contract worth over 7.2 billion yuan for a five-year period, committing to purchase at least 360,000 tons of raw materials [1] - Hongxin Technology received a project designation letter and procurement contract from a major domestic automotive brand [1] - Meihe Co. obtained a patent for a device used in supporting automatic flipping on conveyor lines in the automotive manufacturing sector [1] - Xin Hongye's subsidiary won a bid for an electrical penetration project worth 40.8831 million yuan [1] - Fuan Pharmaceutical's subsidiary received a drug registration certificate for an injection used in liver disease treatment [1] Group 4 - Tianzhong Precision's subsidiary's bankruptcy liquidation application was accepted by the court due to insufficient assets to cover debts [1] - Zhonghong Medical's subsidiary received medical device registration for infusion pumps and information collection systems [1] - Keda Li's subsidiary completed a capital increase, raising its registered capital from 200 million yuan to 400 million yuan [1] - Xingye Technology applied for a credit limit of 372 million yuan from Guangfa Bank [1] - Hengrui Medicine signed a collaboration agreement with GSK, involving a potential total payment of approximately 12 billion USD based on project milestones [1]

Core Viewpoint - Fu'an Pharmaceutical (300194) announced that its wholly-owned subsidiary, Zhichu Pharmaceutical, has received a drug registration certificate from the National Medical Products Administration for an injectable drug, Adenosylmethionine Bisulfate, which is indicated for conditions related to liver cirrhosis and intrahepatic cholestasis during pregnancy [1] Group 1 - The drug is specified in a dosage of 0.5g and has the approval number H20254936 [1] - The acquisition of this drug registration certificate will enhance the product line of the subsidiary and improve its market competitiveness [1] - There are uncertainties regarding the production and sales of the product, as well as its specific impact on the company's performance, due to factors such as pharmaceutical policies and market environment changes [1]